Document is current
Any future updates will be listed below
-
Authors
Terheyden, Jan Henrik
Gittel, Lisa
Jungblut, Julie
Taylor, Deanna J.
Holz, Frank G.
Crabb, David P.
Finger, Robert P.
-
Funding
Funding for this research was provided by:
Universitätsklinikum Bonn
- License Information
-
More Information
Article History
Received: 1 November 2023
Accepted: 8 August 2024
First Online: 17 August 2024
Declarations
:
: Not applicable.
: Not applicable.
: JHT: Carl Zeiss Meditec, CenterVue (now iCare), Heidelberg Engineering, Optos, Novartis, Okko.LG: None.JJ: None.DJT: Apellis.FGH: Acucela, Allergan, Apellis, Bayer, Boehringer-Ingelheim, Bioeq/Formycon, CenterVue (now iCare), Ellex, Roche/Genentech, Geuder, Graybug, Gyroscope, Heidelberg Engineering, IvericBio, Kanghong, LinBioscience, NightStarX, Novartis, Optos, Oxurion Pixium Vision, Oxurion, Stealth BioTherapeutics, Zeiss.DPC: Apellis, Santen, Allergan/Abbvie, Janssen, Thea.RPF: Bayer, Novartis, Roche/Genentech, Alimera, Böhringer-Ingelheim, Santhera, Ellex, Novartis, Zeiss, Heidelberg Engineering, CenterVue (now iCare), Biogen.All outside the submitted work.
